€ in millions 2010 2009 2008 2007 2006
Sales and Earnings
Sales 15,972 14,164 12,336 11,358 10,777
EBIT 2,418 2,054 1,727 1 1,609 1,444
Net income 2 660 1 514 1 450 1 410 330
Depreciation and amortization 639 562 783 421 399
Earnings per ordinary share in € 4.08 1 3.18 1 2.85 1 2.64 2.15 8
Earnings per preference share in € 4.08 1 3.19 1 2.86 1 2.65 2.16 8
Cash flow and Balance sheet
Operating cash flow 1,911 1,553 1,074 1,296 1,052
Operating cash flow in % of sales 12.0% 11.0% 8.7% 11.4% 9.8%
Total assets 23,577 20,882 20,544 15,324 15,024
Non-current assets 17,142 15,519 15,466 11,033 10,918
Equity 3 8,844 7,491 6,943 6,059 5,728
Net debt 8,015 7,879 8,417 5,338 5,611
Net debt / EBITDA 5, 9 2.6 3.0 3.6 2.6 3.0
Equity ratio 3 38% 36% 34% 40% 38%
Investments 4 1,402 931 4,617 1,318 4,314
Profitability
EBIT margin 15.1% 14.5% 14.0% 1 14.2% 13.4%
Return on equity after taxes (ROE) 6, 9, 10 13.3% 12.1% 10.5% 12.0% 10.4%
Return on operating assets (ROOA) 5, 9 11.6% 10.5% 9.8% 11.4% 10.4%
Return on invested capital (ROIC) 5, 9 8.9% 8.2% 7.3% 8.4% 7.4%
Dividend per ordinary share in € 0.86 7 0.75 0.70 0.66 0.57
Employees (December 31) 137,552 130,510 122,217 114,181 104,872
1 2008 before special items from the APP acquisition; 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. Both are non-cash items.
2 Net income attributable to Fresenius SE & Co. KGaA3 Equity including noncontrolling interest4 Investments in property, plant and equipment and intangible assets,
acquisitions5 2006 pro forma Renal Care Group, excluding earnings from the divestiture
of US dialysis clinics as well as their first quarter 2006 earnings
6 2006 pro forma Renal Care Group, excluding first quarter 2006 earnings of divested US dialysis clinics
7 Proposal 8 Adjusted for share split in February 2007 9 2008 pro forma APP Pharmaceuticals and excluding special items from the
APP-acquisition 10 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the
MEB and the CVR
You will find a 10-year overview on our website: www.fresenius.com under “Investor Relations”.
2010 US$ in millions
2009 US$ in millions Change
2010 € in millions
2009 € in millions Change
Sales 12,053 11,247 7% 3,672 3,086 19%
EBIT 1,924 1,756 10% 737 607 21%
Net income 1 979 891 10% 294 200 47%
Operating cash flow 1,368 1,339 2% 567 397 43%
Capital expenditure / acquisitions 1,314 766 72% 205 157 31%
R & D expenses 97 94 3% 143 129 11%
Employees (December 31) 77,442 71,617 8% 22,851 21,872 4%
2010 € in millions
2009 € in millions Change
2010 € in millions
2009 € in millions Change
Sales 2,520 2,416 4% 713 618 15%
EBIT 235 205 15% 41 36 14%
Net income 1 131 107 22% 30 27 11%
Operating cash flow 311 219 42% 47 29 62%
Capital expenditure /acquisitions 179 203 - 12% 14 7 100%
Order intake n / a n / a 625 539 16%
Employees (December 31) 33,321 33,364 0% 3,110 2,849 9%
FRESENIUS MEDICAL CARE
FRESENIUS HELIOS
FRESENIUS KABI
FRESENIUS VAMED
DIALYSIS PRODUCTS,
DIALYSIS CARE
HOSPITAL OPERATION
INFUSION THERAPY, IV DRUGS,
CLINICAL NUTRITION,
MEDICAL DEVICES /
TRANSFUSION TECHNOLOGY
ENGINEERING AND SERVICES
FOR HOSPITALS AND
OTHER HEALTH CARE FACILITIES
1 Net income attributable to the parent company of the respective business segment
Key
figu
res
of t
he b
usin
ess
segm
ents
<
FRESENIUS GROUP IN FIGURES
Fres
eniu
s w
orld
wid
e >
Fresenius Headquarters
Fresenius Medical Care
Fresenius Kabi
Fresenius Helios
Fresenius Vamed
FRESENIUS WORLDWIDE
Major companies and
production plants of the
Fresenius Group.
The figures refer to fiscal
year 2010.
Sales: € 3,672 million Employees: 22,851
Fresenius HemoCare GmbHBad Homburg v. d. H., Germany Fresenius Kabi Deutschland GmbHBad Homburg v. d. H., GermanyFresenius Vial S.A.S.Brézins, FranceFresenius Kabi France S.A.S.Sèvres, FranceFresenius Kabi Italia S.p.A.Verona, ItalyFresenius Kabi Anti-Infectives S.r.l.Cernusco sul Naviglio, ItalyFresenius Kabi Ltd.Runcorn / Cheshire, Great BritainFresenius Kabi Nederland B.V.’s-Hertogenbosch, NetherlandsFresenius HemoCare Netherlands B.V.Emmen, NetherlandsFresenius Kabi N.V.Schelle, BelgiumFresenius Kabi (Schweiz) AGStans, SwitzerlandFresenius Kabi Austria GmbHGraz, Austria
Fresenius Kabi España S.A.Barcelona, SpainLabesfal - Laboratórios Almiro, S.A.Campo de Besteiros, PortugalFresenius Kabi Polska Sp. z o.o.Warsaw, PolandFresenius Kabi ABStockholm, SwedenFresenius Kabi Norge A / SHalden, NorwayFresenius Kabi Pharmaceuticals Holding, Inc. Wilmington / Delaware, USACalea Ltd. Toronto / Ontario, CanadaFresenius Kabi Brasil Ltda.São Paulo, BrazilFresenius Hemocare Brasil Ltda.São Paulo, BrazilLaboratorio Sanderson S.A.Santiago de Chile, ChileFresenius Kabi México S.A. de C.V.Guadalajara, Mexico
Sales: US$ 12,053 millionEmployees: 77,442
Further information on the companies and production plants of Fresenius Medical Care AG & Co. KGaA can be found in the company’s annual report.
Beijing Fresenius Kabi Pharmaceutical Co., Ltd. Beijing, ChinaSino-Swed Pharmaceutical Corp. Ltd. Wuxi, ChinaFresenius Kabi Oncology Ltd.New Delhi, IndiaFresenius Kabi Korea Ltd.Seoul, KoreaFresenius Kabi Australia Pty Ltd.Sydney, AustraliaFresenius Kabi South Africa (Pty) Ltd.Midrand, South Africa
FRESENIUS KABIFRESENIUS MEDICAL CARE
Sales: € 2,520 million Employees: 33,321
The HELIOS Group owns63 clinics, thereof maximum care clinics in:Berlin, GermanyErfurt, GermanyKrefeld, GermanySchwerin, GermanyWuppertal, Germany
FRESENIUS HELIOS
Sales: € 713 million Employees: 3,110
VAMED Group hascompanies / subsidiaries in:Vienna, AustriaBerlin, GermanyMadrid, SpainLisbon, PortugalArnheim, NetherlandsPrague, Czech RepublicNovi Sad, SerbiaTuzla, Bosnia-HerzegovinaBucharest, RomaniaMoscow, RussiaKiev, Donetsk, UkraineAstana, KazakhstanAshgabat, TurkmenistanBaku, AserbaijanAnkara, TurkeyBuenos Aires, ArgentinaBeijing, ChinaKuala Lumpur, MalaysiaBangkok, ThailandHanoi, VietnamJakarta, IndonesiaManila, PhilippinesAbuja, NigeriaLibreville, GabonTripoli, LibyaAbu Dhabi, UAE
FRESENIUS VAMED
€ in millions 2010 2009 2008 2007 2006
Sales and Earnings
Sales 15,972 14,164 12,336 11,358 10,777
EBIT 2,418 2,054 1,727 1 1,609 1,444
Net income 2 660 1 514 1 450 1 410 330
Depreciation and amortization 639 562 783 421 399
Earnings per ordinary share in € 4.08 1 3.18 1 2.85 1 2.64 2.15 8
Earnings per preference share in € 4.08 1 3.19 1 2.86 1 2.65 2.16 8
Cash flow and Balance sheet
Operating cash flow 1,911 1,553 1,074 1,296 1,052
Operating cash flow in % of sales 12.0% 11.0% 8.7% 11.4% 9.8%
Total assets 23,577 20,882 20,544 15,324 15,024
Non-current assets 17,142 15,519 15,466 11,033 10,918
Equity 3 8,844 7,491 6,943 6,059 5,728
Net debt 8,015 7,879 8,417 5,338 5,611
Net debt / EBITDA 5, 9 2.6 3.0 3.6 2.6 3.0
Equity ratio 3 38% 36% 34% 40% 38%
Investments 4 1,402 931 4,617 1,318 4,314
Profitability
EBIT margin 15.1% 14.5% 14.0% 1 14.2% 13.4%
Return on equity after taxes (ROE) 6, 9, 10 13.3% 12.1% 10.5% 12.0% 10.4%
Return on operating assets (ROOA) 5, 9 11.6% 10.5% 9.8% 11.4% 10.4%
Return on invested capital (ROIC) 5, 9 8.9% 8.2% 7.3% 8.4% 7.4%
Dividend per ordinary share in € 0.86 7 0.75 0.70 0.66 0.57
Employees (December 31) 137,552 130,510 122,217 114,181 104,872
1 2008 before special items from the APP acquisition; 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. Both are non-cash items.
2 Net income attributable to Fresenius SE & Co. KGaA3 Equity including noncontrolling interest4 Investments in property, plant and equipment and intangible assets,
acquisitions5 2006 pro forma Renal Care Group, excluding earnings from the divestiture
of US dialysis clinics as well as their first quarter 2006 earnings
6 2006 pro forma Renal Care Group, excluding first quarter 2006 earnings of divested US dialysis clinics
7 Proposal 8 Adjusted for share split in February 2007 9 2008 pro forma APP Pharmaceuticals and excluding special items from the
APP-acquisition 10 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the
MEB and the CVR
You will find a 10-year overview on our website: www.fresenius.com under “Investor Relations”.
2010 US$ in millions
2009 US$ in millions Change
2010 € in millions
2009 € in millions Change
Sales 12,053 11,247 7% 3,672 3,086 19%
EBIT 1,924 1,756 10% 737 607 21%
Net income 1 979 891 10% 294 200 47%
Operating cash flow 1,368 1,339 2% 567 397 43%
Capital expenditure / acquisitions 1,314 766 72% 205 157 31%
R & D expenses 97 94 3% 143 129 11%
Employees (December 31) 77,442 71,617 8% 22,851 21,872 4%
2010 € in millions
2009 € in millions Change
2010 € in millions
2009 € in millions Change
Sales 2,520 2,416 4% 713 618 15%
EBIT 235 205 15% 41 36 14%
Net income 1 131 107 22% 30 27 11%
Operating cash flow 311 219 42% 47 29 62%
Capital expenditure /acquisitions 179 203 - 12% 14 7 100%
Order intake n / a n / a 625 539 16%
Employees (December 31) 33,321 33,364 0% 3,110 2,849 9%
FRESENIUS MEDICAL CARE
FRESENIUS HELIOS
FRESENIUS KABI
FRESENIUS VAMED
DIALYSIS PRODUCTS,
DIALYSIS CARE
HOSPITAL OPERATION
INFUSION THERAPY, IV DRUGS,
CLINICAL NUTRITION,
MEDICAL DEVICES /
TRANSFUSION TECHNOLOGY
ENGINEERING AND SERVICES
FOR HOSPITALS AND
OTHER HEALTH CARE FACILITIES
1 Net income attributable to the parent company of the respective business segment
Key
figu
res
of t
he b
usin
ess
segm
ents
<
FRESENIUS GROUP IN FIGURES
Fres
eniu
s w
orld
wid
e >
Fresenius Headquarters
Fresenius Medical Care
Fresenius Kabi
Fresenius Helios
Fresenius Vamed
FRESENIUS WORLDWIDE
Major companies and
production plants of the
Fresenius Group.
The figures refer to fiscal
year 2010.
Sales: € 3,672 million Employees: 22,851
Fresenius HemoCare GmbHBad Homburg v. d. H., Germany Fresenius Kabi Deutschland GmbHBad Homburg v. d. H., GermanyFresenius Vial S.A.S.Brézins, FranceFresenius Kabi France S.A.S.Sèvres, FranceFresenius Kabi Italia S.p.A.Verona, ItalyFresenius Kabi Anti-Infectives S.r.l.Cernusco sul Naviglio, ItalyFresenius Kabi Ltd.Runcorn / Cheshire, Great BritainFresenius Kabi Nederland B.V.’s-Hertogenbosch, NetherlandsFresenius HemoCare Netherlands B.V.Emmen, NetherlandsFresenius Kabi N.V.Schelle, BelgiumFresenius Kabi (Schweiz) AGStans, SwitzerlandFresenius Kabi Austria GmbHGraz, Austria
Fresenius Kabi España S.A.Barcelona, SpainLabesfal - Laboratórios Almiro, S.A.Campo de Besteiros, PortugalFresenius Kabi Polska Sp. z o.o.Warsaw, PolandFresenius Kabi ABStockholm, SwedenFresenius Kabi Norge A / SHalden, NorwayFresenius Kabi Pharmaceuticals Holding, Inc. Wilmington / Delaware, USACalea Ltd. Toronto / Ontario, CanadaFresenius Kabi Brasil Ltda.São Paulo, BrazilFresenius Hemocare Brasil Ltda.São Paulo, BrazilLaboratorio Sanderson S.A.Santiago de Chile, ChileFresenius Kabi México S.A. de C.V.Guadalajara, Mexico
Sales: US$ 12,053 millionEmployees: 77,442
Further information on the companies and production plants of Fresenius Medical Care AG & Co. KGaA can be found in the company’s annual report.
Beijing Fresenius Kabi Pharmaceutical Co., Ltd. Beijing, ChinaSino-Swed Pharmaceutical Corp. Ltd. Wuxi, ChinaFresenius Kabi Oncology Ltd.New Delhi, IndiaFresenius Kabi Korea Ltd.Seoul, KoreaFresenius Kabi Australia Pty Ltd.Sydney, AustraliaFresenius Kabi South Africa (Pty) Ltd.Midrand, South Africa
FRESENIUS KABIFRESENIUS MEDICAL CARE
Sales: € 2,520 million Employees: 33,321
The HELIOS Group owns63 clinics, thereof maximum care clinics in:Berlin, GermanyErfurt, GermanyKrefeld, GermanySchwerin, GermanyWuppertal, Germany
FRESENIUS HELIOS
Sales: € 713 million Employees: 3,110
VAMED Group hascompanies / subsidiaries in:Vienna, AustriaBerlin, GermanyMadrid, SpainLisbon, PortugalArnheim, NetherlandsPrague, Czech RepublicNovi Sad, SerbiaTuzla, Bosnia-HerzegovinaBucharest, RomaniaMoscow, RussiaKiev, Donetsk, UkraineAstana, KazakhstanAshgabat, TurkmenistanBaku, AserbaijanAnkara, TurkeyBuenos Aires, ArgentinaBeijing, ChinaKuala Lumpur, MalaysiaBangkok, ThailandHanoi, VietnamJakarta, IndonesiaManila, PhilippinesAbuja, NigeriaLibreville, GabonTripoli, LibyaAbu Dhabi, UAE
FRESENIUS VAMED
Top Related